Valuation : Cantargia AB

Market Cap 394M 40.69M 35.06M 33.2M 30.09M 56.45M 3.89B 56.74M 152M 1.98B 153M 149M 6.25B P/E 2026 *
-2.52x
P/E 2027 * -2.48x
Enterprise Value 394M 40.69M 35.06M 33.2M 30.09M 56.45M 3.89B 56.74M 152M 1.98B 153M 149M 6.25B EV / Sales 2026 *
986x
EV / Sales 2027 * 10.9x
Free-Float
97.06%
Yield 2026 *
-
Yield 2027 * -
1 day-0.94%
1 week-10.14%
Current month-13.24%
1 month-12.28%
3 months-26.57%
6 months-60.55%
Current year-62.10%
1 week 1.57
Extreme 1.57
1.78
1 month 1.57
Extreme 1.57
2.1
Current year 1.57
Extreme 1.57
6.59
1 year 1.57
Extreme 1.57
6.59
3 years 1
Extreme 1
6.59
5 years 1
Extreme 1
25.56
10 years 1
Extreme 1
71.8
Manager TitleAgeSince
Chief Executive Officer 60 01/09/2025
Director of Finance/CFO 56 15/06/2023
Chief Tech/Sci/R&D Officer - 02/10/2025
Director TitleAgeSince
Chairman 66 01/01/2016
Director/Board Member 55 01/01/2018
Director/Board Member 66 01/10/2020
Date Insider Type Main position Quantity % Market Cap. Importance
22/06/26 Buy

Chief Technology Officer

18,238 0.0073%
22/06/26 Exercice

Director

-74,997 0.0302%
02/04/26 Free

Chief Technology Officer

80,000 0.0322%
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%-10.14%-39.92%-59.33% 40.69M
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.36%-3.67%+23.59%+216.79% 27.05B
Weighted average by Cap. -0.56%-2.83%+31.24%+170.62%

Financials

2026 *2027 *
Net sales 400K 41.28K 35.57K 33.68K 30.53K 57.27K 3.94M 57.56K 154K 2.01M 155K 152K 6.34M 36.05M 3.72M 3.21M 3.04M 2.75M 5.16M 355M 5.19M 13.86M 181M 13.97M 13.67M 571M
Net income -159M -16.36M -14.1M -13.35M -12.1M -22.7M -1.56B -22.82M -60.97M -795M -61.45M -60.11M -2.51B -151M -15.54M -13.39M -12.68M -11.49M -21.55M -1.48B -21.66M -57.89M -755M -58.35M -57.07M -2.39B
Net Debt - -
Logo Cantargia AB
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Employees
22
Date Price Change Volume
11/09/26 SEK 1.586 -0.94% 911,337
10/09/26 SEK 1.601 -4.59% 1,436,052
09/09/26 SEK 1.678 -1.06% 606,963
08/09/26 SEK 1.696 -1.97% 1,422,727
07/09/26 SEK 1.730 -1.98% 796,430
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.586SEK
Average target price
8.250SEK
Spread / Average Target
+420.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CANTA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!